טוען...
Research status on immunotherapy trials of gastric cancer
The breakthrough of immune checkpoint inhibitor (ICI) therapy has created extensive opportunities for cancer immunotherapy. Especially, the block of programmed death-1/programmed death ligand 1 (PD-L1) axis using ICIs has become a new therapeutic strategy to treat advanced gastric cancer (GC). Howev...
שמור ב:
| הוצא לאור ב: | World J Clin Cases |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Baishideng Publishing Group Inc
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8316931/ https://ncbi.nlm.nih.gov/pubmed/34368297 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12998/wjcc.v9.i21.5782 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|